PT  - JOURNAL ARTICLE
AU  - Botwin, Gregory J.
AU  - Li, Dalin
AU  - Figueiredo, Jane
AU  - Cheng, Susan
AU  - Braun, Jonathan
AU  - McGovern, Dermot P.B.
AU  - Melmed, Gil Y.
TI  - Adverse Events Following SARS-CoV-2 mRNA Vaccination Among Patients with Inflammatory Bowel Disease
AID  - 10.1101/2021.03.30.21254607
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.30.21254607
4099  - http://medrxiv.org/content/early/2021/03/31/2021.03.30.21254607.short
4100  - http://medrxiv.org/content/early/2021/03/31/2021.03.30.21254607.full
AB  - Patients with immune-mediated inflammatory diseases (IMID) such as inflammatory bowel disease (IBD) on immunosuppressive and biologic therapies were largely excluded from SARS-CoV-2 mRNA vaccine trials. We thus evaluated post-mRNA vaccination adverse events (AE) in 246 vaccinated adults with IBD participating in a longitudinal vaccine registry. In general, AE frequency was similar to that reported in the general population. As in the general population, AE were more common among younger patients, and those with prior COVID-19. We additionally found that AE were less common in individuals receiving biologic therapy. Those with IBD and other IMID on these commonly prescribed therapies can be reassured that the AE risk is likely not increased, and may be reduced, while on biologics.Competing Interest StatementGB: none. DL: Consultant: Prometheus Bioscience. JF: none. SC: none. JB: Research funding from Janssen. DM: Consultant: Takeda, Boehringer Ingelheim, Palatin Technologies, Bridge Biotherapeutics, Pfizer, Gilead. Consultant and Stockholder: Prometheus Biosciences. GYM: Consultant: Abbvie, Boehringer-Ingelheim, Bristol-Meyers-Squibb, Celgene, Entasis, Janssen, Medtronic, Pfizer, Samsung Bioepis, Takeda, Techlab, Research funding from Pfizer, Crohns and Colitis Foundation. Clinical Trialobservational study, not a clinical trialFunding StatementThis study was supported by the The Leona M. and Harry B. Helmsley Charitable Trust, the Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, and the National Institute of Diabetes and Digestive and Kidney Disease Grants P01DK046763 and U01DK062413. This study has been additionally supported in part by the Cedars-Sinai Precision Health Initiative, the Erika J. Glazer Family Foundation, and through the Serological Sciences Network, grant NCI U54-CA260591.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Cedars-Sinai IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available in the manuscript and supporting files.